Tuberculosis research in the European Union: Past achievements and future challenges

Tuberculosis

Volumn 90, Issue 1, 2010, Pages 1-6

  Lång, Hannu ^a   Quaglio, GianLuca ^a   Olesen, Ole F ^a  

^a Directorate General for Research   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BIOLOGICAL MARKER; RIFAMPICIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; BCG VACCINATION; DIAGNOSTIC TEST; ENDEMIC DISEASE; EUROPEAN UNION; FUNDING; HOST PARASITE INTERACTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; MALARIA; MEDICAL RESEARCH; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; ORGANIZATION; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BIOMEDICAL RESEARCH; CONGRESSES AS TOPIC; EUROPEAN UNION; HUMANS; RESEARCH SUPPORT AS TOPIC; TUBERCULOSIS;

EID: 75149185338     PISSN: 14729792     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tube.2009.10.002     Document Type: Article

References (23)

1. WHO Report 2008: global tuberculosis control-surveillance, planning, financing. hptt//www.who.int/tb/publications/global_report/2008/en/index.html.
2. Matteelli A., Migliori G.B., Cirillo D., Centis R., Girard E., and Raviglione M. Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis: epidemiology and control. Expert Rev Anti Infect Ther 5 (2007) 857-871
3. Gandhi N.R., Moll A., Sturm A.W., Pawinski R., Govender T., Lalloo U., et al. Extensively drug-resistant tuberculosis as a cause of death in patients coinfected with tuberculosis and HIV in rural area of South Africa. Lancet 368 (2006) 1575-1580
4. World Health Organisation. WHO EuropeanMinisterial Forum. The Berlin Declaration on Tuberculosis. EUR/07/5061622/5 Berlin, 22 October 2007. http://www.euro.who.int/document/e90833.pdf.
5. The global plan to stop TB: 2006-2015. WHO 2006. http://www.stoptb.org/globalplan/assets/documents/GlobalPlanFinal.pdf.
6. Raviglione M., and Uplekar M.W. WHO's new Stop TB strategy. Lancet 367 (2006) 952-955
7. Communication from the Commission to the Council and the European Parliament. Programme for action: accelerated action on HIV/AIDS, malaria and tuberculosis in the context of poverty reduction. COM, 2001, 21.2.2001. http://europa.eu.int/eur-lex/en/com/cnc/2001/com20010096en01.pdf.
8. Communication from the Commission to the Council and the European Parliament. A European programme for action to confront HIV/AIDS, malaria and tuberculosis through external action (2007-2011). Communicationfrom the Commission to the Council and the European Parliament. COM/2005/0179. Brussels, 27.04.2005. http://europa.eu/scadplus/leg/en/lvb/r12537.htm.
9. Gryseels B., Zumla A., Troye-Blomberg M., Kieny M.P., Quaglio G.L., Holtel A., et al. European Union conference on poverty-related diseases research. Lancet Infect Dis 9 (2009) 334-337
10. Medaglini D., and Hoeveler A. The European research effort for HIV/AIDS, malaria and tuberculosis. Vaccine 21 (2003) S2/116-/120
11. European Commission. Combating deadly diseases: EU funded projects on poverty-related diseases HIV/AIDS, malaria, tuberculosis, 3rd ed. Luxemburg: Office for official publications of the European Communities; 2006. http://ec.europa.eu/research/health/infectious-diseases/poverty-diseases/doc/catalogue-3rdcall_en.pdf.
12. Communication from the Commission to the European Parliament and the Council on the progress report on the 'European and Developing Countries Clinical Trials Partnership' Programme. COM/2008/688/. http://eur-lex. europa.eu/LexUriServ/LexUriServ.do?uri=SEC:2008:2724:FIN: EN:PDF.
13. Medaglini D., Olesen O.F., and Rappuoli R. The European effort towards the development of mucosal vaccines for poverty-related diseases. Vaccine 27 (2009) 2641-2648
14. Cockburn I., and Henderson R. Public-private interaction and the productivity of pharmaceutical research. National bureau of economic research (NBER) working paper 6018 (1997), NBER, Cambridge, MA
15. European Commission. Challenges for the future: research on HIV/AIDS malaria and tuberculosis. http://ec.europa.eu/research/conferences/2008/poverty-related-diseases/index_en.html.
16. Zumla A, Wallis R, Doherty M, Klein N, Parida S, Olesen O, et al. Joint TDR/EC expert consultation on biomarkers in tuberculosis: report of the joint TDR/EC expert consultation to evaluate the potential roles of biomarkers in the management of HIV-infected and HIV-uninfected patients with tuberculosis. Geneva, Switzerland, July 2008. http://apps.who.int/tdr/publications/tdr-research publications/biomarkers/pdf/biomarkers.pdf.
17. Wallis R.S., Doherty T.M., Onyebujoh P., Vahedi M., Laang H., Olesen O., et al. Biomarkers for tuberculosis disease activity, cure, and relapse. Lancet Infect Dis 9 (2009) 162-172
18. Young D.B., Perkins M.D., Duncan K., and Barry III C.E. Confronting the scientific obstacles to global control of tuberculosis. J Clin Invest 118 (2008) 1255-1265
19. Olesen O.F., Lonnroth A., and Mulligan B. Human vaccine research in the European Union. Vaccine 2 (2009) 640-645
20. Hoft D.F. Tuberculosis vaccine development: goals, immunological design, and evaluation. Lancet 372 (2008) 164-175
21. Guy E.S., and Mallampalli A. Managing TB in the 21st century: existing and novel drug therapies. Ther Adv Respir Dis 2 (2008) 401-408
22. McIlleron H., Meintjes G., Burman W.J., and Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. J Infect Dis 196 (2007) S63-S75
23. Kaufmann S.H.E., and Parida S.K. Changing funding patterns in tuberculosis. Nature Medicine 13 (2007) 299-303